Rezdiffra (Resmetirom) Cost in New Jersey: Pricing, Insurance, and Savings in 2026

What Does Rezdiffra (Resmetirom) Cost at New Jersey Pharmacies?

The manufacturer list price for Rezdiffra is $3,500 per month, set by Madrigal Pharmaceuticals. Across New Jersey retail pharmacies in 2026, the average cash-pay price matches this figure at $3,500 per month, with little variation between chains and independent pharmacies.

This price applies to both the 80 mg and 100 mg tablet strengths. The FDA-approved dosing is weight-based: patients weighing less than 100 kg take 80 mg once daily, while those at or above 100 kg take 100 mg once daily 1. Unlike many specialty drugs that require infusion or injection, Rezdiffra is a simple oral tablet taken each morning, which keeps administration costs low but does not reduce the drug acquisition price.

For context, $3,500 per month translates to $42,000 per year before insurance. That annual figure places Rezdiffra in a mid-tier specialty drug bracket. It is less expensive than many biologics used in hepatology (obeticholic acid listed at roughly $6,000 per month before its manufacturer's withdrawal) but far above generic statins or vitamin E, which have been used off-label for fatty liver disease at under $30 per month 2.

The sticker price rarely reflects what insured patients actually pay. The sections below break down what New Jersey residents can expect after insurance, Medicaid, and manufacturer assistance.

Does New Jersey Medicaid Cover Rezdiffra?

Yes. New Jersey Medicaid covers Rezdiffra with prior authorization (PA). The PA requirement means that prescribers must document specific clinical criteria before Medicaid will approve the claim.

New Jersey's Medicaid Preferred Drug List (PDL) does not place Rezdiffra on formulary without restrictions, given its cost and the specificity of its indication. Prescribers typically need to submit documentation showing a confirmed diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis stage F2 or F3, evidence that the patient has attempted lifestyle modifications, and results from non-invasive testing (such as FibroScan or the Enhanced Liver Fibrosis test) or liver biopsy 1.

PA turnaround times for NJ FamilyCare (the state's Medicaid program) typically range from 24 to 72 hours for standard requests. Urgent requests can be processed within 24 hours. If denied, patients have the right to appeal through a fair hearing process under New Jersey administrative code.

One practical consideration: not all NJ Medicaid managed care organizations (MCOs) process Rezdiffra claims identically. Amerigroup, Aetna Better Health, Horizon NJ Health, UnitedHealthcare Community Plan, and WellCare each manage their own formularies under NJ FamilyCare. Patients should confirm coverage with their specific MCO before assuming approval 3.

Which Commercial Insurance Plans Cover Rezdiffra in New Jersey?

Most major commercial plans in New Jersey now include Rezdiffra on specialty formulary tiers, though coverage terms vary. Horizon Blue Cross Blue Shield of New Jersey, the state's largest insurer, covers Rezdiffra as a specialty pharmacy benefit with prior authorization and step therapy requirements. Patients generally must show documented MASH with fibrosis staging.

UnitedHealthcare, Aetna, and Cigna plans sold in New Jersey also cover Rezdiffra, although each uses different PA criteria. Step therapy may require documentation of lifestyle interventions (diet, exercise, weight management) before approval. Some plans require that the prescriber be a hepatologist or gastroenterologist, while others accept prescriptions from primary care with specialist consultation notes.

Copay tiers matter. On most NJ commercial plans, Rezdiffra falls under Tier 4 or Tier 5 (specialty), which typically means coinsurance of 25% to 33% rather than a flat copay. Without manufacturer assistance, a patient on a 30% coinsurance tier would owe $1,050 per month. That is where the Madrigal savings card becomes critical.

The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance states: "Resmetirom is recommended for adults with noncirrhotic NASH with moderate to advanced fibrosis (stage F2 to F3)" 4. This guideline language supports PA approvals, and NJ-based prescribers should reference it directly in authorization submissions.

How Does the Madrigal Pharmaceuticals Savings Card Work in New Jersey?

Madrigal offers a copay savings program for commercially insured patients prescribed Rezdiffra. Eligible patients in New Jersey can reduce their out-of-pocket costs to as low as $0 per month. The card covers the difference between the patient's copay or coinsurance and the $0 target, up to a maximum annual benefit (typically capped at $13,000 to $15,000 per year, depending on the program terms in effect).

Eligibility requirements are straightforward. Patients must have commercial insurance (not Medicaid, Medicare, TRICARE, or other government-funded programs), be a resident of a state where the card is accepted (New Jersey qualifies), and have a valid Rezdiffra prescription. The card can be activated through the Madrigal Pharmaceuticals website or by calling the support line printed on prescription materials.

There are limitations to know. The savings card does not apply to patients on Medicare Part D. Federal anti-kickback statutes prohibit manufacturer copay cards for federally funded insurance programs, and this restriction applies in New Jersey just as it does nationwide. Medicare Part D patients in NJ who need cost assistance should explore Medicare Extra Help (Low-Income Subsidy), which can reduce specialty tier copays substantially.

Patients using the savings card should also be aware of accumulator adjuster programs. Some NJ commercial plans (particularly self-insured employer plans administered by major PBMs like CVS Caremark and Express Scripts) use copay accumulator adjustments that prevent manufacturer card payments from counting toward the patient's annual out-of-pocket maximum 5. If a plan uses an accumulator, the patient may face a cost cliff midyear when the card's annual cap is reached.

Is Compounded Resmetirom Legal in New Jersey?

Compounded resmetirom is available in New Jersey through licensed 503A compounding pharmacies. This is legal under both federal and New Jersey state pharmacy law, provided the pharmacy holds a valid NJ Board of Pharmacy compounding license and dispenses pursuant to a patient-specific prescription.

A few important distinctions. Compounded resmetirom is not FDA-approved Rezdiffra. It is a pharmacy-prepared version of the same active ingredient, but it has not undergone the same manufacturing controls, bioequivalence testing, or FDA inspection as the branded product. The FDA has not challenged 503A compounding of resmetirom as of May 2026, but this status could change if enforcement priorities shift.

Cost is the primary motivator. Some NJ 503A pharmacies offer compounded resmetirom at substantially lower prices than the branded product. Pricing varies by pharmacy, but reported figures range from a few hundred dollars per month down to near-cost levels for patients who pay cash.

Dr. Zobair Younossi, a leading MASH researcher and chair of the Global NASH Council, has noted: "Access to MASH therapies remains a barrier for many patients. The gap between list price and patient ability to pay is one of the biggest challenges in hepatology today" 3. This observation is directly relevant to NJ patients weighing branded versus compounded options.

Patients should discuss compounded resmetirom with their prescriber. The clinical data from the MAESTRO-NASH trial used the branded formulation, so efficacy assumptions for compounded versions rely on pharmaceutical equivalence rather than trial data 3.

What Did the MAESTRO-NASH Trial Show?

The MAESTRO-NASH trial (N=966) is the key phase 3 study that led to Rezdiffra's FDA approval in March 2024. Published in the New England Journal of Medicine, the trial randomized adults with biopsy-confirmed NASH and fibrosis stage F1B, F2, or F3 to resmetirom 80 mg, resmetirom 100 mg, or placebo once daily 3.

At 52 weeks, 25.9% of patients on resmetirom 80 mg and 29.9% on resmetirom 100 mg achieved NASH resolution with no worsening of fibrosis, compared to 9.7% on placebo (P<0.001 for both comparisons). For the fibrosis improvement endpoint, 24.2% on the 80 mg dose and 25.9% on the 100 mg dose achieved at least a one-stage reduction in fibrosis with no worsening of NAS, versus 14.2% on placebo 3.

These results are significant because no prior drug had demonstrated both histological NASH resolution and fibrosis improvement in a phase 3 trial. The dual-endpoint achievement was the basis for the FDA's accelerated approval.

LDL cholesterol also dropped meaningfully. Patients on resmetirom 100 mg saw a 22% reduction in LDL-C from baseline, an effect linked to resmetirom's activation of the thyroid hormone receptor beta in the liver. Triglycerides fell by approximately 19% 3. These lipid benefits are clinically relevant because cardiovascular disease is the leading cause of death in MASH patients, not liver failure 6.

Side effects were generally mild. Diarrhea (27% vs. 19% placebo) and nausea (19% vs. 12% placebo) were the most commonly reported adverse events. Serious adverse events occurred at similar rates across groups 3.

Can I Get Rezdiffra via Telehealth in New Jersey?

Yes. New Jersey permits telehealth prescribing of Rezdiffra. The state's telehealth parity laws, expanded during the COVID-19 public health emergency and made permanent through legislation signed in 2021 (NJ P.L. 2021, c.139), allow licensed prescribers to evaluate patients and prescribe medications including controlled and non-controlled specialty drugs via audio-video telehealth visits.

Rezdiffra is not a controlled substance, so there are no DEA-related telehealth prescribing restrictions. A New Jersey-licensed physician, nurse practitioner, or physician assistant can prescribe it after a telehealth evaluation that includes review of the patient's liver imaging, lab work (ALT, AST, FIB-4 index), and relevant history.

For patients in southern or rural NJ counties with limited hepatology access, telehealth can connect them with specialists at academic centers like Rutgers Robert Wood Johnson or Cooper University Health Care without requiring in-person travel. This is especially relevant given that MASH diagnosis and fibrosis staging increasingly rely on non-invasive tools (FibroScan, MRE, blood-based panels) rather than mandatory liver biopsy 7.

Telehealth does not change the insurance authorization process. PA requirements, formulary tiers, and copay obligations remain the same whether the prescription originates from an in-person or telehealth visit.

Practical Steps to Minimize Rezdiffra Costs in New Jersey

Getting the lowest price on Rezdiffra in NJ requires a systematic approach. Start with insurance verification: call the member services number on the back of your card and ask specifically whether resmetirom (Rezdiffra) is on formulary, what tier it occupies, and what PA criteria apply.

If you have commercial insurance, activate the Madrigal savings card before your first fill. Ask your pharmacist to run the savings card as secondary to your insurance at the point of sale. Confirm with your plan whether it uses a copay accumulator or copay maximizer program, because this changes the long-term cost math.

If you are on NJ Medicaid (NJ FamilyCare), have your prescriber submit the PA with documentation of fibrosis staging (F2 or F3), failed lifestyle modification, and AASLD guideline references. Include the NAS score if available from biopsy 4.

For uninsured or underinsured patients, contact Madrigal's patient access program directly. Ask about free drug programs for patients below income thresholds. Simultaneously, explore 503A compounding pharmacy options in NJ, but discuss bioequivalence considerations with your prescriber first.

The AASLD practice guidance recommends that "treatment decisions should be made collaboratively between the clinician and patient, incorporating patient values, preferences, and the balance of benefits and harms" 4. Cost is a legitimate factor in that shared decision-making conversation.

New Jersey-Specific Regulatory Considerations

New Jersey has several pharmacy and insurance regulations that affect Rezdiffra access specifically. The state's step therapy reform law (NJ S.B. 2279, enacted 2019) allows patients and prescribers to request an exception to step therapy requirements if the required first-line treatment is contraindicated, has been tried and failed, or is expected to be ineffective based on the patient's medical history 8.

This is directly relevant to Rezdiffra. If a plan requires trial of vitamin E or pioglitazone before approving Rezdiffra, the prescriber can file a step therapy exception. For patients with diabetes (who should not receive pioglitazone due to fluid retention risks) or those with vitamin E contraindications, the exception pathway is well supported.

New Jersey's specialty pharmacy laws also require that patients be given a choice of specialty pharmacy when their plan mandates specialty pharmacy dispensing. Rezdiffra is commonly dispensed through specialty channels (CVS Specialty, Optum Specialty, Accredo), and NJ patients have the right to request a specific in-network specialty pharmacy if preferred.

The NJ Department of Banking and Insurance oversees commercial plan compliance with these requirements. Patients who believe their plan is improperly denying coverage can file complaints through the department's online portal.

Long-Term Cost Outlook for Rezdiffra in New Jersey

Rezdiffra's current pricing reflects its status as a first-in-class therapy with no generic competition. Madrigal holds composition-of-matter patents on resmetirom that extend into the early 2030s, meaning branded generic competition is unlikely before 2032 at the earliest.

Two factors could change the cost picture before then. First, additional MASH drugs are in late-stage development. Survodutide (Boehringer Ingelheim), semaglutide for MASH (Novo Nordisk, separate from the obesity indication), and several FGF21 analogs are in phase 3 trials with potential approval timelines between 2026 and 2028 9. Competition tends to moderate pricing, especially when payers gain formulary alternatives.

Second, CMS drug price negotiation under the Inflation Reduction Act could eventually include Rezdiffra. The IRA allows Medicare to negotiate prices for high-spend, single-source drugs that have been on the market for at least 9 years (small molecules) or 13 years (biologics). Resmetirom, as a small molecule approved in 2024, would become eligible for negotiation no earlier than 2033.

For NJ patients filling Rezdiffra prescriptions today, the annual cost after the Madrigal savings card for commercially insured patients is typically $0 to $1,500, depending on plan design. Medicaid patients pay $0 to nominal copays ($1 to $3 per fill). Uninsured patients face the full $42,000 annual cost unless they qualify for patient assistance or choose a compounded alternative.